RxDoctor Payments Data

Tiffany Moore, APRN

Psychiatric/Mental Health · Lancaster, NHNPI 1609502699

Payments from drug & device makers

$546in general payments, 2019–2025

Across 25 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • Neurocrine Biosciences, Inc.$28
  • Otsuka America Pharmaceutical, Inc.$25
  • Novo Nordisk$23
  • Indivior Inc.$22
  • Alkermes, Inc.$22
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$546 in reported general payments places this provider in the 55th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$1,548
Medicare patients
11
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl18$9,029
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl36$4,721
Mirtazapine96$1,616
Aripiprazole67$1,277
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine25$1,276
Duloxetine Hcl50$1,116
Olanzapine101$766
Buspirone Hcl29$510
Venlafaxine Hcl ErVenlafaxine Hcl17$297
Bupropion Hcl SrBupropion Hcl15$232
Lamotrigine34$224
Sertraline Hcl47$216
Clonazepam43$162
Escitalopram Oxalate16$123
Gabapentin17$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$22$9,02918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Lancaster

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →